Prathamesh Pathak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prathamesh Pathak has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Amit G. Singal
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
1 shared publication Bruce Feinberg
Cardinal Health , Dublin, OH 43017
1 shared publication- Bruce Feinberg
Cardinal Health, Dublin, OH 43017, USA
1 shared publication - Danielle Gentile
Department of Supportive Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
1 shared publication - Federica Edith Pisa
Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
1 shared publication John Galvin
Incyte Corporation , Wilmington, DE 19803
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States
Background: Outcomes may differ among patients with diffuse large B-cell lymphoma (DLBCL) based on race and ethnicity; however, individuals from diverse racial and ethnic backgrounds have historically been underrepresented in clinical trials. This study describes the real-world characteristics, treatment patterns, and outcomes of patients treated with tafasitamab, an anti-CD19 monoclonal antibody for relapsed or refractory (R/R) DLBCL, by race and ethnicity. Methods: A descriptive subgroup analysis by race and ethnicity was conducted from a retrospective, physician-abstracted medical chart review study. Patients were aged ≥18 years, initiated tafasitamab treatment for R/R DLBCL on/after October 21, 2020, and had ≥4 months follow-up; patients who died during follow-up were included. Data were collected from February 22 to March 29, 2023, and from December 18, 2023 to January 31, 2024. Results: The analysis included 181 patients: 64.1% White, 22.1% Black or African American, 7.7% Other (race other than White, Black or African American, or unknown), 6.1% were of unknown race; 82.3% non-Hispanic, 17.1% Hispanic, and 0.6% were of unknown ethnicity. The median (Q1-Q3) follow-up time for the overall study population from tafasitamab initiation was 14.7 (8.5-17.1) months and was relatively similar for all subgroups. Most patients (71.8%) received tafasitamab in second-line and this was true across subgroups. Real-world overall response rates (95% CI) were 73.3% (65.2-81.3), 82.5% (70.7-94.3), 74.5% (67.5-81.5), and 67.7% (51.3-84.2) for White, Black or African American, non-Hispanic, and Hispanic patients, respectively. Conclusions: Findings suggest effectiveness outcomes among patients receiving tafasitamab for R/R DLBCL were consistent across racial and ethnic groups.
- 9 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Open AccessReal-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States
Background: Outcomes may differ among patients with diffuse large B-cell lymphoma (DLBCL) based on race and ethnicity; however, individuals from diverse racial and ethnic backgrounds have historically been underrepresented in clinical trials. This study describes the real-world characteristics, treatment patterns, and outcomes of patients treated with tafasitamab, an anti-CD19 monoclonal antibody for relapsed or refractory (R/R) DLBCL, by race and ethnicity. Methods: A descriptive subgroup analysis by race and ethnicity was conducted from a retrospective, physician-abstracted medical chart review study. Patients were aged ≥18 years, initiated tafasitamab treatment for R/R DLBCL on/after October 21, 2020, and had ≥4 months follow-up; patients who died during follow-up were included. Data were collected from February 22 to March 29, 2023, and from December 18, 2023 to January 31, 2024. Results: The analysis included 181 patients: 64.1% White, 22.1% Black or African American, 7.7% Other (race other than White, Black or African American, or unknown), 6.1% were of unknown race; 82.3% non-Hispanic, 17.1% Hispanic, and 0.6% were of unknown ethnicity. The median (Q1-Q3) follow-up time for the overall study population from tafasitamab initiation was 14.7 (8.5-17.1) months and was relatively similar for all subgroups. Most patients (71.8%) received tafasitamab in second-line and this was true across subgroups. Real-world overall response rates (95% CI) were 73.3% (65.2-81.3), 82.5% (70.7-94.3), 74.5% (67.5-81.5), and 67.7% (51.3-84.2) for White, Black or African American, non-Hispanic, and Hispanic patients, respectively. Conclusions: Findings suggest effectiveness outcomes among patients receiving tafasitamab for R/R DLBCL were consistent across racial and ethnic groups.
- 19 January 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (3) , 349-357
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies are needed. This retrospective cohort study included 550 patients with uHCC in the US who initiated 1L atezo+bev between June 2020 and April 2023. Medical records were abstracted to describe treatment patterns and outcomes. Of 294 patients who discontinued 1L therapy, 176 patients initiated 2L therapy (2L cohort) and 48 patients didn't initiate 2L therapy after ≥8 weeks of follow-up (No 2L cohort). More of the No 2L cohort had Stage IVb tumors, BCLC stage D, ECOG-PS ≥2, ascites, and hepatic encephalopathy at baseline. The 2L cohort were more likely to discontinue atezo+bev due to disease progression (92.1% vs. 56.3%), and less likely due to toxicity/intolerability (4.0% vs. 10.4%) than the No 2L cohort. OS from 1L atezo+bev initiation was significantly longer in the 2L cohort vs. No 2L cohort (median 23.0 vs. 14.3 months; p < 0.001]). 1L Atezo+bev was clinically active with 256 patients remaining on therapy at last follow-up. Patients who progressed after 1L atezo+bev benefited from additional systemic therapies. Future research analyzing the comparative effectiveness of 2L therapies is needed.
- 19 January 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (3) , 349-357
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies are needed. This retrospective cohort study included 550 patients with uHCC in the US who initiated 1L atezo+bev between June 2020 and April 2023. Medical records were abstracted to describe treatment patterns and outcomes. Of 294 patients who discontinued 1L therapy, 176 patients initiated 2L therapy (2L cohort) and 48 patients didn't initiate 2L therapy after ≥8 weeks of follow-up (No 2L cohort). More of the No 2L cohort had Stage IVb tumors, BCLC stage D, ECOG-PS ≥2, ascites, and hepatic encephalopathy at baseline. The 2L cohort were more likely to discontinue atezo+bev due to disease progression (92.1% vs. 56.3%), and less likely due to toxicity/intolerability (4.0% vs. 10.4%) than the No 2L cohort. OS from 1L atezo+bev initiation was significantly longer in the 2L cohort vs. No 2L cohort (median 23.0 vs. 14.3 months; p < 0.001]). 1L Atezo+bev was clinically active with 256 patients remaining on therapy at last follow-up. Patients who progressed after 1L atezo+bev benefited from additional systemic therapies. Future research analyzing the comparative effectiveness of 2L therapies is needed.